12:00 AM
 | 
Jun 16, 2008
 |  BioCentury  |  Emerging Company Profile

Miragen: The heart of miRNA

Miragen: The heart of miRNA

By Aaron Bouchie Senior Writer

While currently approved drugs and devices to treat heart failure are palliative, Miragen Therapeutics Inc. is developing drugs against microRNA targets that it believes will be disease modifying. The company raised $8 million in a series A round in May, which should get it to an efficacy study in large animals.

MicroRNAs are noncoding RNAs consisting of 22 nucleic acids that base pair with mRNAs and inhibit translation or promote mRNA degradation. miRNAs that pair perfectly with target mRNA sequences result in mRNA degradation, whereas miRNAs that are not perfectly complementary generally result in translational inhibition.

CEO William Marshall said miRNAs coordinate the expression of sets of genes by targeting multiple mRNAs. Thus, targeting an miRNA should make it possible to affect an entire...

Read the full 649 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >